150 mg/day. When her condition improved she defaulted from follow up, but presented again in June 1992, confined to a wheelchair.
The patient considered that her knee osteoarthritis was responsible for her progressive inability to participate fully in pursuits with her outgoing, sport loving family, and had consulted a private orthopaedic surgeon who undertook synchronous bilateral knee replacements. After her operation, she remained confined to a wheelchair, having failed to regain an ability to walk. When she presented in June 1992, examination showed a profound proximal myopathy such that she was unable to rise from sitting or initiate any upper arm movement. The investigations (table) included a repeat needle muscle biopsy specimen that showed large numbers of atrophic fibres, focal necrosis, the occasional regenerating fibre, marked thickening of the small vessels, and obliteration of small arterioles, with prominent endothelial activation and one focus of active lymphocytic vasculitis. She was treated with intravenous cyclophosphamide plus methylprednisolone and physiotherapy, with some improvement, but remained disabled by the proximal myopathy.
In March 1993, further digital vasculitis was treated with prednisolone and methotrexate (maintenance dose of 20 mg/week). In late April 1994, a blood count (table) persistently high numbers of macrophages, though these contained reduced numbers of inclusion bodies (fewer than five) and culture remained negative. At the time of the patient's discharge from hospital in March 1995, results of laboratory investigations were as shown in the table. At this time the patient's only medication was prednisolone 5 mg/day, and the hepatosplenomegaly resolved over the subsequent six months.
In August 1995, the patient had a recurrence of vasculitis with increasing weakness, and an increase in the CK concentration to 946 IU/1. A repeat bone marrow biopsy examination did not show parasites on microscopy or culture, and she restarted 30 mg prednisolone and methotrexate 20 mg/week, with a good symptomatic response, and a decrease in her CK concentration.
Discussion
The management of this patient was compromised by her personality and desired life style. We were manipulated into management decisions against our better judgment, in particular the monitoring of cytotoxic treatment from the UK whilst the patient was absent on extended vacations in Spain. The patient's personality, in combination with the overfocused approach of the private orthopaedic surgeon, led to synchronous bilateral knee replacements in the face of unrecognised extensive proximal weakness and active digital vasculitis, which continued unrecognised during the patient's rehabilitation in hospital.
In connective tissue diseases, thrombocytopenia, neutropenia, and anaemia, or any combination of these, may be disease related, irrespective of previous drug induced bone marrow toxicity. The use of cytotoxic agents in the management of these conditions demands regular monitoring to detect early signs of bone marrow suppression. Neutropenia with azathioprine is common, whilst methotrexate less frequently causes leucopenia and thrombocytopenia. Pancytopenia with methotrexate is uncommon. Bone marrow biopsying is required to distinguish both between disease and drug effects, and the less common causes of pancytopenia such as infection.
This case demonstrates the relevance of a history of foreign travel, particularly where infection is concerned. Visceral leishmaniasis is endemic on the coast of Malaga and throughout the Mediterranean basin, where the variant Leishmania donovani infantum predominates. The vector is the Phlebotomus sandfly, which is found at the coast, but does not survive at altitude.' In immunocompetent hosts, 96% of cases of leishmaniasis are subclinical, with the development of lifelong immunity to Leishmania donovani. In the indigenous population, the infection presents as Kala-Azar, and can be characterised by anaemia, often with associated leucopenia and thrombocytopenia, usually related to decreased red cell survival and increased cell sequestration in the spleen.2
In visitors to the endemic area, the onset of leishmaniasis is more likely to be abrupt, with .0 high fever, and rapid progression of illness with toxaemia, weakness, dyspnoea, and acute anaemia. Immunocompromised hosts are particularly at risk of severe disease, with rapid progression, and appear to follow a clinical course similar to that observed in this patient. Most of the published cases had AIDS or HIV related immunosuppression, and weight loss, high fever, and pancytopenia were characteristic presentations. Notable features were a lack of splenomegaly, and a failure to mount leshmanial antibody production.3 After treatment, a failure to clear the organism, as revealed by repeat marrow biopsy, was associated with a high incidence of relapse in the immunocompromised host.4 Among those who are transiently immunosuppressed as a result of taking steroids or cytotoxic drugs, one report of three cases showed that two had moved away from the endemic leishmaniasis area before they were given immunosuppressive treatment and subsequently presented with acute fever and pancytopenia, but not splenomegaly, after the instigation of immunosuppression.5 These patients did well after removal of the immunosuppressive agents, and the patient we report here was subsequently managed on the minimum possible dose of steroid, to avoid further drug induced depression of her immune system, and to maximise clearance of the parasite. It 
